AQR Capital Management
ABOS icon

AQR Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

AQR Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-46,292
Closed -$53.7K – 3457
2025
Q2 		$53.7K Buy
46,292
+4,557
+11% +$4.9K ﹤0.01% 3235
2025
Q1 		$45.9K Buy
+41,735
New +$59.6K ﹤0.01% 3086

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

AQR Capital Management's ABOS Position: Q3 2025 in Review

AQR Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q3 2025, closing a stake of 46,292 shares — an estimated $53.7K sold.

AQR Capital Management first reported a position in ABOS in Q1 2025 and held it in 2 quarters. The position peaked at $53.7K in Q2 2025. 69 funds tracked by Wall St. Rank hold ABOS as of Q3 2025.

  • AQR Capital Management reported no remaining Acumen Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 46,292 Acumen Pharmaceuticals shares in Q3 2025, an estimated $53.7K.
  • AQR Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • AQR Capital Management's Acumen Pharmaceuticals position peaked at $53.7K in Q2 2025.
  • 69 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.